1 / 18

PROSTAGLANDINS MS.NAGESWARARAO

PROSTAGLANDINS MS.NAGESWARARAO DEPT OF CLINICAL PHARMACOLOGY. PROSTAGLANDINS AND LEUKOTRIENES (EICOSANOIDS ) Prostaglandins (PGs) and Leukotrienes (LTs) are biologically active

lpenick
Download Presentation

PROSTAGLANDINS MS.NAGESWARARAO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROSTAGLANDINS MS.NAGESWARARAO DEPT OF CLINICAL PHARMACOLOGY

  2. PROSTAGLANDINS AND LEUKOTRIENES (EICOSANOIDS) • Prostaglandins (PGs) and Leukotrienes (LTs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids that are released from cell membrane phospholipids • They are the major lipid derived autacoids • CHEMISTRY, BIOSYNTHESIS AND DEGRADATION • Chemically, PGs may be considered to be derivatives of prostanic acid, though prostanoic acid does not naturally occur in the body • It has a five membered ring and two side chains projecting in opposite directions at right angle to the plane of the ring

  3. Leukotrienesare so named because they were first obtained from leukocytes (leuko) and have 3 conjugated double bonds (triene) • In the body PGs, TXs and LTs are all derived from eicosa (referring to 20 C atoms) tri/tetra/pentaenoic acids • Therefore, they can be collectively called eicosanoids

  4. In human tissues, the fatty acid released from membrane lipids in largest quantity is arachidonic acid • During PG, TX and prostacyclin synthesis, 2 of the 4 double bonds of arachidonic acid get saturated in the process of cyclization, leaving 2 double bonds in the side chain • No cyclization or reduction of double bonds occurs during LT synthesis – the LTs of biological importance are LTB4, LTC4, LTD4.

  5. There are no preformed stores of PGs and LTs • They are synthesized locally at rates governed by the release of arachidonic acid from membrane lipids in response to appropriate stimuli • These stimuli activate hydrolases, including phospholipase A, probably through intracellular Ca2+..

  6. The cyclooxygenase (COX) pathway generates eicosanoids with a ring structure (PGs, TXs, prostacyclin) while lipoxygenase (LOX) produces open chain compounds (LTs) • Cyclooxygenase is now known to exist in two isoforms COX-1 and COX-2. • While both isoforms catalyze the same reactions, COX-1 is a constitutive enzyme in most cells – its activity is not changed once the cell is fully grown • On the other hand, COX-2 normally present in insignificant amounts, is inducible by cytokines, growth factors and other stimuli during the inflammatory response

  7. It is believed that eicosanoids produced by COX-1 participate in physiological (house keeping) functions such as secretion of mucus for protection of gastric mucosa, haemostasis and maintenance of renal function, • While those produced by COX-2 lead to inflammatory and other pathological changes • However, certain sites in kidney and brain constitutively express COX-2 which may play physiological role • Lipoxygenase pathway appears to operate mainly in the lung, WBC and platelets

  8. INHIBITION OF SYNTHESIS: Synthesis of COX products can be inhibited by nonsteroidalanti-inflammatory drugs (NSAIDs) • Aspirin acetylates COX at a serine residue and causes irreversible inhibition while other NSAIDs are competitive and reversible inhibitors • Most NSAIDs are nonselective COX-1 and COX-2 inhibitors, but some newer ones like celecoxib, rofecoxib are selective for COX-2 • NSAIDs do not inhibit the production of LTs: this may even be increased since all the arachidonic acid becomes available to the LOX pathway

  9. Glucocorticoids inhibit the release of arachidonic acid from membrane lipids (by stimulating production of proteins called annexins or lipocortinswhich inhibit phospholipase A2)–indirectly reduce production of all eicosanoids – PGs, TXs, and LTs • DRGRADATION: of arachidonates occurs rapidly in most tissues, but fastest in the lungs • Metabolites are excreted in urine

  10. USES • Clinical use of PGs and their analogues is rather restricted because of limited availability, short lasting action, cost, side effects and other practical considerations. Their approved indications are • 1. ABORTION: During first trimester, termination of pregnancy by transcervical suction is the procedure of choice • Intravaginal PGE2 pessary inserted 3 hours before attempting dilatation can minimize trauma to the cervix by reducing resistance to dilatation • Gemeprost or dinoprostone(PGE2-tab,gel etc) is used intravaginally to soften the cervix before operative procedure. • Second trimester : Dinoprostone(PGE2),Dinoprost(PGF2α) or carboprost(15-methyl PGF2α) are used in mild term abortion, missed abortion and molar pregnancy. – increases uterine contractions and soften the cervix,

  11. Uterine contractions are provoked and the conceptus is expelled within the next few hours • Third trimester : induction of labour –oxytocin is the drug of choice .PGs used when there is contraindication for the use of oxytocin. • Uterine cramps, vaginal bleeding, nausea, vomiting and diarrhoea are the possible complications • 2. INDUCTION / AUGMENTATION OF LABOUR: PGs do not offer any advantage over oxytocin for induction of labour at term • PGE2 and PGF2α (rarely) have been used in place of oxytocin in renal failure patients, because they do not cause fluid retention

  12. 3. CERVICAL PRIMING: Applied intravaginally or in the cervical canal, low doses of PGE2 which do not affect uterine motility make the cervix soft and compliant • This procedure has yielded good results in cases with unfavourable cervix • 4. POSTPARTUM HAEMORRHAGE (PPH): Carboprost (15 Methyl PGF2α) injected i.m. is an alternative for control of PPH due to uterine atony, especially in patients unresponsive to ergometrine and oxytocin • PREP:15-methyl PGF2α (Carboprost) 0.25 mg in 1 ml amp, • DOSE: 0.25 mg i.m. every 30-120 min for PPH, mid term abortion, missed abortion

  13. 5. PEPTIC ULCER: Stable analogue of PGE1 (misoprostol) is occasionally used for healing peptic ulcer, especially in patients who need continued NSAID therapy or who continue to smoke • 6. GLAUCOMA: Topical PGF2α analogues like latanoprost are one of the first choice drugs in wide angle glaucoma • PREP: 0.5 mg in 1 ml; dilute and infuse i.v. • 7. TO AVOID PLATELET DAMAGE:PHI2 (Epoprostenol) can be used to prevent platelet aggregation and damage during haemodialysis or cardiopulmonary bypass

  14. It also improves harvest of platelets for transfusion • Few cases of primary pulmonary hypertension have been successfully maintained on epoprostenolinfusion (Decreases peripheral,pulmonary and coronary resistance) • PREP: 0.5 mg vial for reconstitution • 9) Impotence :PGE1 (alprostadil) is useful in the treatment of erectile disfuncton. • SIDE EFFECTS: Side effects are common in the use of PGs, but their intensity varies with the PG, the dose and the route • These are: nausea, vomiting, watery diarrhoea, uterine cramps, unduly forceful uterine contractions, vaginal bleeding, flushing, shivering, fever, malaise, fall in BP, tachycardia, chest pain

  15. PREPERATIONS FORMULATIONS USES OF PGs: • Dinoprostone(PGE2) Vaginal tab and gel induction of labour/midturm of abortion • Dinoprost (PGF2α) intra-amniotic inj mid term abortion • Carboprost intra-amniotic inj mid term abortion/PPH (15-methyl PGF2α) • Gameprost(PGE1) vaginal pessary cervical priming • Alprostadil(PGE1) iv.infusion& intracavarnous inj PDA/Impotence • Misoprostol(PGE1) oral peptic ulcer/abortion • Epoprostenol(PGI2) i.v infusion pulmonary hypertension • Latanoprost(PGF2α) Topical Glaucoma

More Related